Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).
Giaccone G, Debruyne C, Felip E, Chapman PB, Grant SC, Millward M, Thiberville L, D'addario G, Coens C, Rome LS, Zatloukal P, Masso O, Legrand C. Giaccone G, et al. Among authors: chapman pb. J Clin Oncol. 2005 Oct 1;23(28):6854-64. doi: 10.1200/JCO.2005.17.186. J Clin Oncol. 2005. PMID: 16192577 Clinical Trial.
Vaccinating patients with autologous tumor.
Chapman PB. Chapman PB. J Clin Oncol. 2002 Oct 15;20(20):4139-40. doi: 10.1200/JCO.2002.20.20.4139. J Clin Oncol. 2002. PMID: 12377956 No abstract available.
A phase II randomized trial of talimogene laherparepvec oncolytic immunotherapy with or without radiotherapy for patients with cutaneous metastases from solid tumors.
Barker CA, D'Angelo SP, Wasilewski G, Steckler AM, Lian M, Zhang Z, Chapman PB, Shoushtari AN, Ariyan CE. Barker CA, et al. Among authors: chapman pb. Radiother Oncol. 2024 Nov;200:110478. doi: 10.1016/j.radonc.2024.110478. Epub 2024 Aug 17. Radiother Oncol. 2024. PMID: 39159678 Clinical Trial.
Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.
Smithy JW, Kalvin HL, Ehrich FD, Shah R, Adamow M, Raber V, Maher CA, Kleman J, McIntyre DAG, Shoushtari AN, Betof Warner A, Callahan MK, Momtaz P, Eton O, Nair S, Wolchok JD, Chapman PB, Berger MF, Panageas KS, Postow MA. Smithy JW, et al. Among authors: chapman pb. Clin Cancer Res. 2024 Aug 15;30(16):3407-3415. doi: 10.1158/1078-0432.CCR-23-3643. Clin Cancer Res. 2024. PMID: 38767650 Clinical Trial.
192 results